ノースカロライナにおける膠芽腫の臨床試験
ノースカロライナ内の拠点で、膠芽腫に関する26件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- University of North Carolina, Chapel Hill
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT05902169Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- East Carolina University, Greenville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07195591Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Comprehensive Cancer Center of Wake Forest*, Winston-Salem
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03970447A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
- Wake Forest University, Winston-Salem
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05139056Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT04903795Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
- Duke University Medical Center, Durham
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06319027A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
- Duke University, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT05708352A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
- Duke University, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06069726Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/20更新 · NCT06177964DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/01更新 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
- Lineberger Comprehensive Cancer Center, Chapel Hill
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/22更新 · NCT05366179Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- Duke University, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/20更新 · NCT06625684SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774D2C7-IT + 2141-V11 Combination Post-resection in rGBM
- Duke University Medical Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/23更新 · NCT06455605D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Duke University Medical Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/06更新 · NCT05734560APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/27更新 · NCT03175224Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Duke University, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2025/06/25更新 · NCT05879367ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。